Skip to main content

Davis Cassandra

Since 2015, CDC’s Division of Health Informatics and Surveillance staff have conducted evaluations to provide information on the utility, functionality, usability and user satisfaction associated with the National Syndromic Surveillance Program’s BioSense Platform tools. The BioSense Platform tools include: 1) Access and Management Center (AMC), a tool that enables site administrators to manage users and data permissions; 2) Electronic Surveillance System for Early Notification of Community-based Epidemics (ESSENCE), a software application that enables syndromic surveillance related data visualization and analysis; 3) Adminer, a tool that allows users to access site data on the datamart; and 4) Rstudio, an application that can be used for data analysis and visualization. The evaluation findings have informed activities that led to improvements in functionality, development or procurement of platform associated tools, and development of resource materials. In May 2018, NSSP conducted an evaluation with eight jurisdictions that participated in the first user acceptance testing (UAT) evaluations in 2015. The purpose of the evaluation was to assess the present status of utility, functionality, usability and user satisfaction of the tools on the BioSense Platform, and delineate progress since 2015.

Objective: To assess the present status of utility, functionality, usability and user satisfaction of the BioSense Platform.

Submitted by elamb on

Syndromic surveillance uses near-real-time Emergency Department healthcare and other data to improve situational awareness and inform activities implemented in response to public health concerns. The National Syndromic Surveillance Program (NSSP) is a collaboration among state and local health departments, the Centers for Disease Control and Prevention (CDC), other federal organizations, and other entities, to strengthen the means for and the practice of syndromic surveillance. NSSP thus strives to strengthen syndromic surveillance at the national and the state, and local levels through the coordinated activities of the involved partners and the development and use of advanced technologies, such as the BioSense platform. Evaluation and performance measurement are crucial to ensure that the various strategies and activities implemented to strengthen syndromic surveillance capacity and practice are effective. Evaluation activities will be discussed at this session and feedback from audience will be sought with the goal to further strengthen evaluation activities in the future. 

Objective:

The objective of this session is to discuss syndromic surveillance evaluation activities. Panel participants will describe contexts and importance of selected evaluation and performance measurement activities in NSSP. Discussions will explore ways to strengthen evaluation in syndromic surveillance activities in the future.

Submitted by elamb on

BioSense was launched in 2003 by CDC with its primary aim to establish an integrated system of nationwide public health surveillance for the early detection and prompt assessment of potential bioterrorism-related syndromes or other public health emergencies. With the release of CDC’s Surveillance Strategy, BioSense evolved into the National Syndromic Surveillance Program (NSSP). To overcome the challenges experienced throughout the integration of local and state level data to produce a real-time national all-hazards surveillance, CDC sought input from the National Syndromic Surveillance Community of Practice (NSSP CoP). They requested that CDC provide advanced syndromic surveillance functionalities and analytical applications, such as ESSENCE and SAS to improve the BioSense Platform. In response, CDC led this pilot project to: 1) conduct security testing of SAS and ESSENCE in order to identify vulnerabilities; 2) test and improve a limited set of processes that occur before data are transformed; and 3) conduct testing of ESSENCE’s functions to ensure the tool worked as intended, and that it will meet user needs.

Objective

To describe the results of a pilot project that examined selected BioSense 2.0 data processing rules and tested SAS and ESSENCE products in the BioSense platform.

Submitted by teresa.hamby@d… on
Subscribe to Davis Cassandra